Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo Academic Article uri icon

Overview

MeSH Major

  • Acute Coronary Syndrome
  • Peptides
  • Protein Kinase Inhibitors
  • p38 Mitogen-Activated Protein Kinases

abstract

  • ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk.

authors

publication date

  • May 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ahj.2015.02.002

PubMed ID

  • 25965710

Additional Document Info

start page

  • 631

end page

  • 638.e7

volume

  • 169

number

  • 5